Oncotarget

Clinical Research Papers:

Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome

Yi-Jhih Huang, Tsai-Wang Huang, Tsu-Yi Chao, Yu-Shan Sun, Shyi-Jou Chen, Der-Ming Chu, Wei-Liang Chen and Li-Wei Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:78144-78152. https://doi.org/10.18632/oncotarget.17839

Metrics: PDF 1230 views  |   HTML 1747 views  |   ?  


Abstract

Yi-Jhih Huang1, Tsai-Wang Huang1, Tsu-Yi Chao2,3, Yu-Shan Sun4, Shyi-Jou Chen5, Der-Ming Chu5, Wei-Liang Chen6,7,8 and Li-Wei Wu6,7,8

1Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C)

2Division of Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C)

3Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, Republic of China (R.O.C)

4Division of Family Medicine, Tri-Service General Hospital Penghu Branch, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C)

5Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C)

6Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China (R.O.C)

7Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China (R.O.C)

8Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China (R.O.C)

Correspondence to:

Li-Wei Wu, email: [email protected]

Keywords: metabolic syndrome, tartrate-resistant acid phosphatase

Received: March 16, 2017    Accepted: April 12, 2017    Published: May 12, 2017

ABSTRACT

Background: Tartrate-resistant phosphatase isoform 5a is expressed in tumor-associated macrophages and is a biomarker of chronic inflammation. Herein, we correlated serum tartrate-resistant phosphatase isoform 5a levels with metabolic syndrome status and made comparisons with traditional markers of inflammation, including c-reactive protein and interleukin-6.

Methods: One hundred healthy volunteers were randomly selected, and cut-off points for metabolic syndrome related inflammatory biomarkers were determined using receiver operating characteristic curves. Linear and logistic regression models were subsequently used to correlate inflammatory markers with the risk of metabolic syndrome.

Results: Twenty-two participants met the criteria for metabolic syndrome, and serum tartrate-resistant phosphatase isoform 5a levels of >5.8 μg/L were associated with metabolic syndrome (c-statistics, 0.730; p = 0.001; 95% confidence interval, 0.618–0.842). In addition, 1 μg/L increases in tartrate-resistant phosphatase isoform 5a levels were indicative of a 1.860 fold increase in the risk of metabolic syndrome (p = 0.012).

Conclusions: Elevated serum tartrate-resistant phosphatase isoform 5a levels are associated with the risk of metabolic syndrome, with a cut-off level of 5.8 μg/L.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17839